Royalty Report: Drugs, Disease – Collection: 367566


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 367566

License Grant
Licensor of Japan grants by way of sub-license and license to Licensee, a sole and exclusive, license under the Patent Rights and the Licensor Technical Information & Know-How to make, have made, offer to provide and provide, develop, manufacture, use, market, sell and offer to sell the Preparation in Licensee Territory.
License Property
Licensor is an exclusive licensee, in certain countries or areas of the world including U.S.A., of certain rights to the human ophthalmic pharmaceutical specialty ecabet sodium in topical preparations for topical ophthalmic applications by way of an agreement with another Party.

Compound shall mean a certain chemical compound having its chemical structure of (+) – (1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethly-7-(1-methylethyl)-6-sulfo-1-
phenanthrenecarboxylic acid 6-sodium salt pentahydrate, which is commonly named ecabet sodium.

Field of Use
The field of use of ecabet sodium product is the treatment of dry eye syndrome.

The rights are for ecabet sodium, a prescription eye drop for the treatment of dry eye syndrome (keratoconjunctivitis sicca, or KCS). Licensor’s ecabet sodium eye drop product is currently in Phase II testing in Japan for the treatment of dry eye and is already marketed in Japan as an oral agent for gastric ulcers and gastritis.

IPSCIO Record ID: 260605

License Grant
The Israel Licensor granted the Israel Licensee an exclusive license to develop the LO2A licensed technology.  LO2A is used for the treatment of Dry Eye Syndrome. The Licensee will develop products in the field of ophthalmic disorders, and mutually agree upon a manufacturer and will purchase, market, sell and distribute LO2A in finished product form in the territories.
License Property
The Licensed Technology includes products in the field of ophthalmic disorders including LO2A,  used in the treatment of dry eye.
Field of Use
Clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders.

IPSCIO Record ID: 291185

License Grant
For the Development License, the Licensor grants to the Licensee of Japan, during the term of the Development Program, the exclusive license, with the right to grant sublicenses in accordance with the terms of this Agreement, under the Licensed Technology, to conduct the Development Program.

For the Commercialization License, Licensor grants an exclusive license throughout the Territory, with the right to grant sublicenses, under the Licensed Technology, to develop, use, manufacture, register, market and sell Products in the Field; provided, however, that nothing  grants Licensee the right to manufacture the Compound used in the manufacture of the Products.

License Property
Compound shall mean the chemical compound designated as INS365, whose chemical name is P1, P4-Di(uridine 5-tetraphosphate), and all sodium salts thereof.

The patents include Method of Treating Dry Eye Disease with Purinergic Receptor Agonists, and, Method for Large-Scale Production of Di(Uridine 5- Tetraphosphate) and Salts Thereof.

Field of Use
The Field shall mean the therapeutic treatment of ocular surface diseases, including dry eye, regardless of how caused, in humans.

IPSCIO Record ID: 239016

License Grant
Japanese Licensor shall transfer and assign any and all title and interest in the Governmental Approval to Licensee and shall grant Licensee an exclusive license to manufacture, import, market, promote, sell and distribute the Preparation under the Governmental Approval. Such license shall include exclusive right to use the Patent Right and Technical Information & Know-How to the extent that it is necessary for the sole purpose of manufacturing, importing, marketing, promoting, selling and distributing the ophthalmic product containing the Compound in the Territory.
License Property
The chemical compound is named timolol.  Timolol is a medication used either by mouth or as eye drops.

Preparation shall mean any ophthalmic product containing the Compound as an active ingredient, which is formulated and manufactured under the Patent Rights.

Field of Use
This agreement is for the sole purpose of manufacturing, importing, marketing, promoting, selling and distributing the ophthalmic product  an ophthalmic product for the treatment of glaucoma.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.